Combined social communication therapy at home and in education for young autistic children in England (PACT-G): a parallel, single-blind, randomised controlled trial

自闭症 契约 背景(考古学) 干预(咨询) 随机对照试验 心理学 单盲板 医学 家长培训 临床心理学 精神科 儿科 考古 古生物学 外科 历史 生物
作者
Jonathan Green,Kathy Leadbitter,Ceri Ellis,Lauren Taylor,Heather Moore,Sophie Carruthers,Kirsty James,Carol Taylor,Matea Balabanovska,Sophie Langhorne,Catherine Aldred,Vicky Slonims,Victoria Grahame,Jeremy Parr,Neil Humphrey,Patricia Howlin,Helen McConachie,Ann Le Couteur,Tony Charman,Richard Emsley,Andrew Pickles
出处
期刊:The Lancet Psychiatry [Elsevier]
卷期号:9 (4): 307-320 被引量:13
标识
DOI:10.1016/s2215-0366(22)00029-3
摘要

Autistic children can have difficulty generalising treatment effects beyond the immediate treatment context. Paediatric Autism Communication Therapy (PACT) has been successful when delivered in the clinic. Here we tested the Paediatric Autism Communication Therapy-Generalised (PACT-G) intervention combined between home and education settings for its overall effect and mechanistic transmission of effect across contexts.In this parallel, single-blind, randomised, controlled trial, we recruited autistic children aged 2-11 years in urban or semi-urban areas in Manchester, Newcastle, and London, England. Children needed to meet core autism criteria on Autism Diagnostic Observation Schedule-second edition (ADOS-2) and parent-rated Social Communication Questionnaire (SCQ-lifetime), and children older than 5 years were included if they had intentional communication but expressive language equivalent of age 4 years or younger. Eligible children were randomly assigned (1:1), using block randomisation (random block sizes of 2 and 4) and stratified for site, age (2-4 years vs 5-11 years), and gender, to either PACT-G plus treatment as usual or treatment as usual alone. Research assessors were masked to treatment allocation. The PACT-G intervention was delivered by a therapist in parallel to the child's parents at home and to learning-support assistants (LSA) at their place of education, using both in-person and remote sessions over a 6 month period, to optimise adult-child social interaction. Treatment as usual included any health support or intervention from education or local community services. The primary outcome was autism symptom severity using the ADOS-2, as measured by researchers, at 12 months versus baseline. Secondary outcomes were Brief Observation of Social Communication Change (BOSCC) and dyadic social interaction between child and adult across contexts, both at 12 months. Other secondary outcome measures were assessed using the following composites: language, anxiety, repetitive behaviour, adaptive behaviour, parental wellbeing, child health-related quality of life, and disruptive behaviour. Assessments were done at baseline, 7 months, and 12 months. We used an intention-to-treat (ITT) analysis of covariance for the efficacy outcome measures. Adverse events were assessed by researchers for all trial families at each contact and by therapists in the PACT-G group at each visit. This study is registered with the ISRCTN Registry, ISRCTN 25378536.Between Jan 18, 2017, and April 19, 2018, 555 children were referred and 249 were eligible, agreed to participate, and were randomly assigned to either PACT-G (n=122) or treatment as usual (n=127). One child in the PACT-G group withdrew and requested their data be removed from the study, giving an ITT population of 248 children. 51 (21%) of 248 children were female, 197 (79%) were male, 149 (60%) were White, and the mean age was 4·0 years (SD 0·6). The groups were well balanced for demographic and clinical characteristics. In the PACT-G group, parents of children received a median of 10 (IQR 8-12) home sessions and LSAs received a median of 8 (IQR 5-10) education sessions over 6 months. We found no treatment effect on the ADOS-2 primary outcome compared with treatment as usual (effect size 0·04 [95% CI -0·19 to 0·26]; p=0·74), or researcher-assessed BOSCC (0·03 [-0·25 to 0·31]), language composite (-0·03 [-0·15 to 0·10]), repetitive behaviour composite (0·00 [-0·35 to 0·35]), adaptive behaviour composite (0·01 [-0·15 to 0·18]), or child wellbeing (0·09 [-0·15 to 0·34]). PACT-G treatment improved synchronous response in both parent (0·50 [0·36 to 0·65]) and LSA (0·33 [0·16 to 0·50]), mediating increased child communication with parent (0·26 [0·12 to 0·40]) and LSA (0·20 [0·06 to 0·34]). Child dyadic communication change mediated outcome symptom alteration on BOSCC at home (indirect effect -0·78 [SE 0·34; 95% CI -1·44 to -0·11]; p=0·022) although not in education (indirect effect -0·67 [SE 0·37; 95% CI -1·40 to 0·06]; p=0·073); such an effect was not seen on ADOS-2. Treatment with PACT-G also improved the parental wellbeing composite (0·44 [0·08 to 0·79]) and the child disruptive behaviour composite in home and education (0·29 [0·01 to 0·57]). Adverse events on child behaviour and wellbeing were recorded in 13 (10%) of 127 children in the treatment as usual group (of whom four [31%] were girls) and 11 (9%) of 122 in the PACT-G group (of whom three [33%] were girls). One serious adverse event on parental mental health was recorded in the PACT-G group and was possibly study related.Although we found no effect on the primary outcome compared with treatment as usual, adaptation of the 12-month PACT intervention into briefer multicomponent delivery across home and education preserved the positive proximal outcomes, although smaller in effect size, and the original pattern of treatment mediation seen in clinic-delivered therapy, as well as improving parental wellbeing and child disruptive behaviours across home and school. Reasons for this reduced efficacy might be the reduced dose of each component, the effect of remote delivery, and the challenges of the delivery contexts. Caution is needed in assuming that changing delivery methods and context will preserve an original intervention efficacy for autistic children.National Institute for Health Research and Medical Research Council Efficacy and Mechanism Evaluation Award.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
上官若男应助YE采纳,获得10
1秒前
Jasper应助YaoX采纳,获得10
1秒前
天天快乐应助威武绿真采纳,获得10
1秒前
MADKAI发布了新的文献求助10
1秒前
2秒前
慕青应助April采纳,获得10
2秒前
123完成签到,获得积分10
2秒前
Xu发布了新的文献求助10
2秒前
manan发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
张张完成签到,获得积分10
3秒前
Dream发布了新的文献求助30
3秒前
3秒前
henry完成签到,获得积分10
4秒前
雾蓝发布了新的文献求助10
4秒前
桃子发布了新的文献求助10
4秒前
烟花应助刘星星采纳,获得10
5秒前
一只鱼完成签到,获得积分10
5秒前
YY发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
qianmo完成签到 ,获得积分10
5秒前
jennifercui发布了新的文献求助10
6秒前
rh1006完成签到,获得积分10
6秒前
mrjohn发布了新的文献求助10
6秒前
6秒前
YE完成签到 ,获得积分20
8秒前
李繁蕊发布了新的文献求助10
8秒前
8秒前
8秒前
可可完成签到,获得积分10
8秒前
9秒前
自由寻菱发布了新的文献求助20
10秒前
俏皮元珊发布了新的文献求助10
10秒前
Owen应助YY采纳,获得10
10秒前
优秀的逊发布了新的文献求助10
10秒前
wzm完成签到,获得积分10
11秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527521
求助须知:如何正确求助?哪些是违规求助? 3107606
关于积分的说明 9286171
捐赠科研通 2805329
什么是DOI,文献DOI怎么找? 1539901
邀请新用户注册赠送积分活动 716827
科研通“疑难数据库(出版商)”最低求助积分说明 709740